Evidence map›Paper›PMID 36476348›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2023

HIV-1 reservoir evolution in infants infected with clade C from Mozambique.

Catherine K Koofhethile, Stefano Rinaldi, Yelizaveta Rassadkina, Vinh B Dinh, Ce Gao, Suresh Pallikkuth, Pilar Garcia-Broncano, Lesley R de Armas, Rajendra Pahwa, Nicola Cotugno and 7 more

Open access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

Catherine K KoofhethileRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA; Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.
Stefano RinaldiUniversity of Miami, Miami, Florida, USA.
Yelizaveta RassadkinaRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Vinh B DinhUniversity of Miami, Miami, Florida, USA.
Ce GaoRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Suresh PallikkuthUniversity of Miami, Miami, Florida, USA.
Pilar Garcia-BroncanoRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Lesley R de ArmasUniversity of Miami, Miami, Florida, USA.
Rajendra PahwaUniversity of Miami, Miami, Florida, USA.
Nicola CotugnoAcademic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
Paula VazFundação Ariel Glaser contra o SIDA Pediátrico, Maputo, Mozambique.
Maria Grazia LainFundação Ariel Glaser contra o SIDA Pediátrico, Maputo, Mozambique.
Paolo PalmaAcademic Department of Pediatrics, Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Xu G YuRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Roger ShapiroHarvard TH Chan School of Public Health, Boston, Massachusetts, USA.
Savita PahwaUniversity of Miami, Miami, Florida, USA.
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA; Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: mlichterfeld@partners.org.
University of Miami · USRagon Institute of MGH, MIT and Harvard · USFundação Ariel Glaser Contra o SIDA Pediátrico · MZHarvard University · USBambino Gesù Children's Hospital · ITBrigham and Women's Hospital · USUniversity of Rome Tor Vergata · IT

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GWENDOLYN Barbara SCOTT · 2007 to 2026
$33.8M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Miami MACS-WIHS Combined Cohort Study Clinical Research SiteU01HL146203 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARIA LUISA ALCAIDE, Deborah Lynne Jones · 2019 to 2026
$21.2M
Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
A Pilot Clinical Trial for HIV-1 EradicationU01AI117841 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2015 to 2020
$10.7M
A clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2018 to 2024
$10.4M
Early Infant TreatmentU01AI114235 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2014 to 2020
$5.1M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
FIC NIH HHS D43 TW009610FIC NIH HHS D43 TW010543NHLBI NIH HHS U01 HL146203NIAID NIH HHS K24 AI155233NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI073961NIAID NIH HHS R01 AI120008NIAID NIH HHS R01 AI127347NIAID NIH HHS R01 AI130005NIAID NIH HHS R01 AI152979NIAID NIH HHS U01 AI114235NIAID NIH HHS U01 AI117841NIAID NIH HHS U01 AI135940NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164562NIAID NIH HHS UM1 AI164566NIAID NIH HHS UM1 AI164570NIDDK NIH HHS R01 DK120387
6 · The paper itself

Abstract

backgroundThe persistence of HIV-1-infected cells during antiretroviral therapy is well documented but may be modulated by early initiation of antiretroviral therapy in infants.

methodsHere, we longitudinally analyzed the proviral landscape in nine infants with vertical HIV-1 infection from Mozambique over a median period of 24 months, using single-genome, near full-length, next-generation proviral sequencing.

resultsWe observed a rapid decline in the frequency of intact proviruses, leading to a disproportional under-representation of intact HIV-1 sequences within the total number of HIV-1 DNA sequences after 12-24 months of therapy. In addition, proviral integration site profiling in one infant demonstrated clonal expansion of infected cells harboring intact proviruses and indicated that viral rebound was associated with an integration site profile dominated by intact proviruses integrated into genic and accessible chromatin locations.

conclusionTogether, these results permit rare insight into the evolution of the HIV-1 reservoir in infants infected with HIV-1 and suggest that the rapid decline of intact proviruses, relative to defective proviruses, may be attributed to a higher vulnerability of genome-intact proviruses to antiviral immunity. Technologies to analyze combinations of intact proviral sequences and corresponding integration sites permit a high-resolution analysis of HIV-1 reservoir cells after early antiretroviral treatment initiation in infants.

Indexed as

HIV-1HIV InfectionsHIV SeropositivityCD4-Positive T-LymphocytesDNA, ViralHumansInfantMozambiqueProvirusesViral LoadDNA, ViralEvolutionHIV-1InfantsIntegration sitesReservoir

Identifiers

PMID36476348
PMCPMC9892347
OpenAlexW4310722510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.